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Background: There appears to exist a potentially important interplay between diabetes mellitus (DM) and
Helicobacter pylori (H. pylori) infection. Findings from previous studies have been conflicting. Only a few studies have
examined the topic in a sub-Saharan African population. This study sought to determine the prevalence of H. pylori
infection among Type 2 diabetes mellitus (T2DM) patients in Lagos, Nigeria.
Findings: H. pylori infection was detected in 18% of T2DM patients and 13% of controls but there was no statistical
significance in this difference (p = 0.52). The prevalence of H. pylori was neither associated with the known duration
of T2DM nor was it associated with age, gender, body mass index (BMI), smoking status. T2DM was not shown to
be a risk factor independently associated with risk for H. pylori infection (OR = 0.87, 95% CI = 0.58-1.31, p = 0.57).
Conclusions: The lack of a statistical significant difference between the H. pylori infection rates in T2DM patients
and controls suggests that the infection is not increased in T2DM. Larger studies need to be conducted to confirm
the study findings.
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Since the discovery of the bacterium by Warren and
Marshal in 1984 [1], Helicobacter pylori has been shown
to have a world-wide distribution. It has been estimated
that up to half of the world’s population harbor the in-
fection in their stomachs [2]. The developing world has
a higher prevalence rate of infection than the developed
world and it has associated with both gastrointestinal
and extra-intestinal ailments [3].
An increased prevalence of H. pylori infection among
diabetes mellitus patients was first suggested by a report
from Hungary [4]. It was further supported by other
reports [5,6]. The latter study [6], documented a H. pylori
prevalence rate of 74.4% in Type 2 diabetes mellitus
patients as against 50% in non-diabetic controls. Another
study in Italy corroborated this finding [7]. However,
other more recently published data have concluded
otherwise. A large Australian study [8] showed that there* Correspondence: remioluyemi@yahoo.com
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reproduction in any medium, provided the orwas no significant difference in prevalence of H. pylori
infection in DM versus(vr) non-DM patients. The
higher prevalence of infection among normal children
as opposed to those with type 1 DM [9] further
strengthens this opposing argument especially as child-
hood is thought to be the most common period of acquisi-
tion of H. pylori infection.
An earlier report by Ugwu et al. [10] from Nigeria
examined the possibility of such a relationship in our
local environment. The study reported no significant dif-
ference in the prevalence of H. pylori infection between
diabetics and non-diabetics (35% vr 28%, p> 0.05). The
study was unique as there exists little data examining
this topic in sub-Saharan populations.
The mode of diagnosis that was deployed in this study,
the stool antigen testing, identifies active infection unlike
the serological based modalities of diagnosis which can-
not distinguish between current and previous infections
[11]. This study sought to determine the prevalence of
H. pylori infection among T2DM patients in Lagos,
South-West region of Nigeria.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Socio-Demographic and arthropometric data of










Sex: Male (%) 43 45 0.89









Smoking Status: No (%) 82 80 0.45




Primary (%) 13 22
Secondary (%) Post- 23 27
Secondary (%) 53 42
Table 2 Comparison of H. pylori status among study
participants with type 2 diabetes mellitus and controls in
LUTH, Lagos
Cases(n= 100) Controls(n = 100) Total(=200)
H. pylori POSITIVE 18 13 31
H. pylori NEGATIVE 82 87 169
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The study is a hospital-based, cross-sectional survey and
was conducted at the Lagos University Teaching Hospital
(LUTH), which is situated in Idi-Araba, Lagos State, Ni-
geria. It is the largest tertiary health facility in the com-
mercial nerve centre of Nigeria and it’s catchment area of
patients is state-wide with extension to adjoining states in
the South West region. After obtaining informed consent,
100 consecutive, consenting T2DM patients and 100
controls were recruited from the adult out-patient wing of
LUTH. Age and gender-matched controls were selected
from non-diabetic volunteers among LUTH staff, students
and patients’ relations. The controls were randomly
requested to participate and only consenting ones were
recruited for the study. After agreeing to participate and
signing informed consent forms, all respondents had
standard pretested written questionnaires administered to
them by medical doctors. They were then required to
submit fresh stool samples which were tested for evidence
of active H. pylori infection by stool antigen positivity with
the immunoassay-based Rapid Strip HpSATM according
to the manufacturer’s instructions (from Meridian Bio-
science Europe)(sensitivity 96.1%, specificity 90.6%) [12].
Each of the controls had blood drawn for fasting blood
glucose and those that met the minimum World Health
Organization requirement for diabetes mellitus diagnosis
were excluded from being controls in this study. This mini-
mum criterion is a fasting plasma glucose of≥ 7.1 mmol/l
[13]. As diarrheic stools are not appropriate for testing with
the above mentioned kit [12], this was taken as an exclu-
sion criterion for both cases and controls. Also excluded
were those who had had prior antibiotic and proton pump
therapy for H. pylori infection.
Ethical approval was obtained from the Research and
Ethics Committee of LUTH prior to the commencement
of the study.Data obtained was analyzed using the statis-
tical software Epi-info version 6. Results are expressed as
means ± standard deviation and frequencies. Statistical
analysis was done using the students’ t-test for continu-
ous variables and the chi-squared(x2) for categorical
data. Multivariate analyses were conducted in view of
possible confounding factors.
Findings
Both study cases and controls had similar socio-
demographic and anthropometric profiles and Table 1
summarizes the parameters examined.
Prevalence of Helicobacter pylori infection in cases and
Non-diabetic controls
H. pylori infection as determined by stool antigen posi-
tivity was present in 18%(n = 100) of type 2 diabetic
patients and 13%(n = 100) of the controls(Table 2). There
was no significant difference in overall prevalence ofH. pylori in cases and controls (x2 = 0.41, p = 0.52). Of
the 13 infected control subjects, the prevalence was
higher in men (7/45) than in women(6/55) (15.6% vr
10.9%, x2 = 0.09, p = 0.75). H. pylori-positive control
subjects were not significantly younger than H. pylori-
negative subjects (53.6 ±12.30 vr 55.1 ±10.04 years,
p = 0.84); The overall prevalence of H. pylori infection
was 18% (n= 100) in patients with T2DM. The prevalence
of H. pylori infection was 16.4% (7/43) in men and 21.1%
(12/57) in women with T2DM (x2 =0.06, p =0.81).
The H. pylori-positive type 2 DM patients were noted to
be were slightly older than H. pylori-negative counterparts
in this study but the difference was also not statistically
significant (55.1 ± 9.95 vr 56.7± 10.53 years, p = 0.91).
The prevalence of H. pylori infection was not asso-
ciated with the known duration of T2DM. The preva-
lence of the infection was 26.9% (7/26) in patients with
T2DM diagnosed ≤ 2 years prior, 20.8% (5/24) in those
diagnosed 2–5 years prior, and 14% (7/50) in those diag-
nosed ≥5 year duration(x2 = 1.25, p = 0.52). There were
24 obese T2DM in this study as against 17 in the control
group. H. pylori was positive in 12.5% of obese diabetics
(3/24) and 19.7% (15/76) of diabetics with normal BMI
(x2 = 0.14, p = 0.74). There was no association between
H. pylori infection and smoking history; the prevalence
of the infection was 32.5% (66/203) in those with a
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in non-smokers (x2 = 0.02, p = 0.89).
In patients with diabetes and control subjects, logistic
regression analysis (including age, gender, diabetes status,
BMI, level of education and smoking history) revealed that
not any one of the above mentioned factors was independ-
ently associated with H. pylori infection.
Discussion
Prevalence of H. pylori infection in type 2 diabetes
mellitus patients and controls
There was no significant difference in the prevalence of
H. pylori in cases and controls (x2 = 0.41, p = 0.52). The
results therefore show that H. pylori infection is not sig-
nificantly associated with type 2 diabetes mellitus in this
study population.
Ugwu et al. [10] had reported similar findings from
the South East region of Nigeria as there was no signifi-
cant association between the infection prevalence in
their diabetic population and non-diabetic controls(35%
vr 28% respectively, p = 0.432). The findings are also in
keeping with the results from various other regions of
the world both developed-Australia [8], Italy [9] and
developing-China [14], Turkey [15], Romania [16].
However, there exists in scientific literature, other con-
flicting data as reported by several investigators. In 1989,
Simon et al. [4] reported that infection rates were signifi-
cantly higher in diabetics than in their controls. This was
the first report to examine for a possible relationship
between H. pylori and DM. It used rapid urease test to
detect infection but a major confounder, age, was not
adjusted for in comparison between the groups of patients
and controls.
Current thinking about the natural history of H. pylori
infection is that childhood remains the most important
period of acquisition and that spontaneous clearance of in-
fection occurs with increasing frequency as time pro-
gresses [17,18]. Hence, the role of age in this issue is quite
prominent and it should have been adjusted for before
coming to conclusions about any hypothesized association.
Another report that supported the positive association was
from Oldenburg et al. [19]. A review of this seropositivity-
based paper reveals that there was a significant difference
between the ages of the diabetics and that of the controls
as has also been noted by Xia et al. [8]. Thus, drawing con-
clusions without adjusting for this important variable may
have led to the conclusion of Oldenburg et al. [19] (espe-
cially as their own analysis had showed a significantly
higher prevalence was observed only in the 60–70 year
olds).
The influence of age cannot be overemphasized as for
instance, the initial significantly less prevalence of H. pylori
between the type 1 diabetics and their type 2 counterparts
and even those of controls disappeared when appropriateadjustments for age were made in a large Australian study
[8].
Poor socioeconomic status, living conditions, and hy-
giene have been repeatedly demonstrated to be major risk
factors for H. pylori infection [9,14]. Dore et al. [9] has
also observed that the studies that found an association
between DM and H. pylori infection often did not correct
for this very important confounding variable. Moreover, it
must be noted that the research tool employed for the
detection of H. pylori seropositivity in the Oldenburg et al
study was only 79% specific and this cannot be considered
acceptable by current standards [11].
Local H. pylori infection prevalence data as compared
with study findings
H. pylori prevalence data from local studies vary widely
depending on the population studied and mode of bac-
terial identification.
Seroprevalence studies predominate and their values vary
based on the population studied and mode of H. pylori
diagnosis. The highest and lowest prevalence values were
studies in which the diagnosis of H. pylori was made via
histology in patients undergoing endoscopy. Eighty-seven
percent (78%) was the highest quoted figure and this was
from a hospital-based study among Maiduguri dyspeptics
[20] and the lowest figure of 22.4% was an Ibadan report
from among patients with chronic gastritis [21].
The prevalence figures from this index population
(18% in T2DM patients and 13% in controls) was rather
low as compared to the other prevalence data as indi-
cated above. The reasons may not farfetched.
First, it is not appropriate to compare the prevalence
data from community-based and hospital-based studies as
there remains the inbuilt tendency for bias in doing so.
Various factors which come to play in hospital-based stud-
ies cannot be easily corrected for during data analysis. Also
the hospital-base from which the study participants are
drawn lends itself to the explanation that there is a higher
likelihood of these patients being exposed to repeated anti-
biotics that might have anti-helicobacter effects [22]. The
mode of diagnosis is also an issue as serology-based stud-
ies cannot compensate for the inability of the tests to dis-
tinguish between current and previous infection [23]. The
stool antigen detection basis of this study represents an at-
tempt at more accurate detection of prevalence of current
H. pylori infection in our local population. This was also
corroborated by Smith et al [24] in their study of the use
of stool antigen test to diagnose H. pylori infection.
H. pylori infection and duration of diabetes
This study does not agree with the suggestion that the
prevalence of H. pylori infection increases with the dur-
ation of diabetes. There was no relationship between dur-
ation of DM and H. pylori infection. This was in agreement
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ture [8,9,15]. There still exists controversy in this area as
some researchers have noted a significant relationship be-
tween H. pylori infection and DM duration [5,25] while
others have noted a negative relationship [22].
The Italian study [25] showed that the prevalence of H.
pylori infection was 23%, 32%, and 40% in patients with
type 1 diabetes who had a disease duration of >1 year, 1–
3 year, or >3 year, respectively [26]. The age factor, again,
appears to have confounded the results of these studies.
The mean ages in the above mentioned groups were 22,
30, and 37 years, respectively, and it is likely that any associ-
ation between H. pylori infection and duration of DM
would disappear if age was adjusted for in the final analyses.
The negative association report [22] was seroprevalence-
based and conducted among type 1 diabetics from Spain.
The seroprevalence of H. pylori infection was 43% in
patients with the duration of <3 yr and the rate decreased
to 16% for those with a longer duration. The reason adduced
for this was that infection decreases during the course of
DM disease because of repeated antibiotic therapy.
This study does not support the hypothesis that patients
with DM are more frequently infected by H. pylori over time.
Conclusions
The lack of a statistical significant difference between the
H. pylori infection rates in T2DM patients and controls
suggests that the infection is not increased in T2DM.
More empowered and larger studies need to be conducted
to confirm the study findings and further elucidate the re-
lationship of these two factors- T2DM and H. pylori
infection.
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